TBPMF - Study: Canadians Receptive to Pharma Cannabis Options
Canadians know of the benefits from medical treatments with cannabis, but still want confirmation from their doctors, according to a new survey made public on Tuesday (February 26).
The poll commissioned by Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF), a life science cannabis firm, found two in three Canadians are willing to use pharmaceutical drugs with cannabis if prescribed by a doctor.
However, this optimism goes down if the cannabis-based medicine were to not be covered by a public or private insurance.
The study results showed only four in 10 of respondents would still be interested in securing pharmaceutical products with cannabis if these were not covered.
Steeve Neron, senior vice president of marketing and medical affairs with Tetra Bio-Pharma, told the Investing News Network (INN) the study was conducted to take a snapshot of how receptive Canadian patients are to cannabis in pharmaceuticals.
Neron explained data from clinical trials will open the doors to the adoption of medicine with cannabis elements.
When asked if a similar study could be run with bigger parameters covering more Canadians, Neron the company is exploring the option but it would be a costly endeavour.
The results, from the just over 2,000 people polled, also found Canadians are unsure their doctor is “up-to-date on cannabis treatments.”
Tetra Bio-Pharma projects further improvement to treatments thanks to clinical trials in the space will help establish a trust for cannabis therapies with the medical community at large.
“Treatment with cannabis is complex, which is why the pharmaceutical pathway [ensure] precise dosing and consistent formulation,” Guy Chamberland, CEO of the company, said in a press release.
Last year, GW Pharmaceuticals provided a landmark moment for the medical cannabis space after its drug candidate, epidiolex, was approved by the US Food and Drug Administration (FDA).
This CBD-based medicine is designed to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two-years-old and older.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.